Cutaneous Leishmaniasis Clinical Trial
Official title:
A Blinded, Placebo Controlled Study Evaluating Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen (LtSTA)
Verified date | October 2013 |
Source | Nielsen BioSciences, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The efficacy of LtSTA as a skin test antigen depends upon the sensitivity and specificity of the product. This study has been designed to measure the skin test responses to 15, 30, or 50µg doses of LtSTA. The measurements of non-specific reactivity due to components of the antigen solution and the product's ability to sensitize lymphocytes of Leishmania naïve persons when administered intradermally. The presence or absence of a local inflammatory response to the first skin test with each of three doses of LtSTA will provide insight on the specificity of the antigen in a naïve population. The local inflammatory response to LtSTA following the first and second repeat skin tests will indicate if the antigen is sensitizing after intradermal administration.
Status | Completed |
Enrollment | 50 |
Est. completion date | January 2010 |
Est. primary completion date | September 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Male or Female in good health; - Age 18 - 60 years; - No past history of leishmaniasis or prior participation in a Leishmania study; - No prior skin test with a Leishmania antigen; - No occupational, residential, or travel exposure to Leishmania; - Positive CandinĀ® or Trichophyton skin test (>= 5 mm induration). Exclusion Criteria: - History of adult atopic dermatitis, contact dermatitis to multiple agents, unexplained urticaria, or asthma; - Active allergic rhinitis or conjunctivitis; - History of allergy or reactions to phenol, polysorbate 80, or glycerol; - Medications: currently taking (within the last month) antihistamines or recent history of taking (within the last 1 year) corticosteroids, immunosuppressants; - Splenectomy; - Active medical disease*; *Active Medical Disease: Any active physical or psychiatric condition that may increase the risks associated with participation in the study or interferes with the interpretation of study results. Included chronic medical illnesses are cardiovascular disease, renal insufficiency, chronic respiratory illness, cirrhosis, chronic hepatitis, chronic pancreatitis, chronic diarrhea, malnutrition, malignancy, autoimmune disease, and asthma. - Pregnancy or lactating; - Immunization within 4 weeks; - History of leishmaniasis; - Occupational exposure to Leishmania; - Prior participation in a Leishmania study; - Prior skin test with Leishmania antigen; - Travel history to Leishmania endemic areas; - Abnormal screening lab results; - Keloid scar formation |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening
Country | Name | City | State |
---|---|---|---|
United States | California Research Foundation | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
Nielsen BioSciences, Inc. | U.S. Army Medical Research and Materiel Command |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitizing Effects of LtSTA in Leishmania Naive Adults | Skin test response of subjects in the trial were evaluated 48 hours post injection after each of three skin test given at 30 day intervals in naive individuals (no exposure to the Leishmania organism). (Actual times 0, 30 and 60 days).The outcome measure was designated as number of participants who became sensitized to the Leishmania antigen. This is defined as those participants that had a negative skin test result, followed by a positive response in a subsequent skin test without having been exposed to the Leishmania organism. | 62 days | No |
Secondary | The Safety of 15, 30 and 50µg/0.1mL Doses of LtSTA in Healthy Adult Volunteers Who Have Had no Known Previous Exposure to Leishmania Parasites | Local and systemic events following skin test. Local: burning, itching, pain. Systemic: Body aches, dizziness, nausea, weakness. | 74 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01988909 -
WR 279,396 for the Treatment of Cutaneous Leishmaniasis
|
Phase 2 | |
Enrolling by invitation |
NCT00840359 -
Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis
|
Phase 2 | |
Enrolling by invitation |
NCT00737386 -
Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The West Bank
|
N/A | |
Completed |
NCT00233545 -
Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
|
Phase 2 | |
Completed |
NCT01462500 -
Pharmacokinetics of Miltefosine in Children and Adults
|
Phase 4 | |
Completed |
NCT01011309 -
A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT01301924 -
Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02281669 -
Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients
|
N/A | |
Completed |
NCT01464242 -
Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis
|
Phase 2/Phase 3 | |
Completed |
NCT01790659 -
Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
|
Phase 3 | |
Completed |
NCT01050907 -
Miltefosine to Treat Mucocutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT04340128 -
Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)
|
Phase 3 | |
Terminated |
NCT00317629 -
Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
|
Phase 3 | |
Completed |
NCT00351520 -
Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica
|
Phase 3 | |
Completed |
NCT01381055 -
Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis
|
Phase 2/Phase 3 | |
Completed |
NCT01050777 -
Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis
|
Phase 0 | |
Completed |
NCT01380314 -
Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis
|
Phase 2 | |
Terminated |
NCT01380301 -
Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony
|
Phase 2 | |
Completed |
NCT00703924 -
Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
|
Phase 2 | |
Completed |
NCT00344084 -
Surveillance for Leishmaniasis Skin Lesions in Mali
|